title: Association between the XPD/ERCC2 Lys751Gln polymorphism and risk of cancer: evidence from 224 case-control studies.
abstract: Genetic variations in the xeroderma pigmentosum group D (XPD) gene may increase cancer susceptibility by affecting the capacity for DNA repair. A lot of studies have reported the association of XPD Lys751Gln polymorphism with risk of cancer, but the results remained controversial. Hence, we performed a systematic review and conducted a meta-analysis to explore association of the XPD Lys751Gln polymorphism with risk of cancer (78,398 cases and 103,178 controls from 224 studies). Overall, a significantly increased cancer risk was found in all genetic models (dominant model: odds ratio (OR) = 1.10, 95% confidence interval (CI) = 1.06-1.14; recessive model: OR = 1.10, 95% CI = 1.05-1.15; homozygous model: OR = 1.14, 95% CI = 1.08-1.21; heterozygous model: OR = 1.09, 95% CI = 1.05-1.12; additive model: OR = 1.08, 95% CI= 1.05-1.11) when all eligible studies were pooled into the meta-analysis. In further stratified and sensitivity analyses, the elevated risk of cancer remained for subgroups of breast cancer, esophageal cancer, hepatocellular cancer, leukemia, lung cancer, and melanoma. In summary, this meta-analysis suggests the XPD Lys751Gln polymorphism is a genetic susceptibility for some cancer types. Moreover, ethnicity, histological type of cancer, and smokers seem to contribute to varying expressions of the Lys751Gln on some cancer risk. In addition, our work also points out the importance of new studies for Lys751Gln association in endometrial cancer and ovarian cancer, where at least some of the covariates responsible for heterogeneity could be controlled, to obtain a more conclusive understanding about the function of the Lys751Gln polymorphism in cancer development.
authors.affiliation: Department of Integrative Medicine of Traditional Chinese Medicine and Western Medicine, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
authors.forename: Kai-Ge
authors.initials: KG
authors.lastname: Wu
authors.forename: Xiao-Feng
authors.initials: XF
authors.lastname: He
authors.forename: Yun-Hui
authors.initials: YH
authors.lastname: Li
authors.forename: Wei-Bin
authors.initials: WB
authors.lastname: Xie
authors.forename: Xi
authors.initials: X
authors.lastname: Huang
mesh_terms: D016022:Case-Control Studies; D020022:Genetic Predisposition to Disease; D006801:Humans; D015201:Meta-Analysis as Topic; D009369:Neoplasms / Q000235:genetics*; D011110:Polymorphism, Genetic / Q000235:genetics*; D011379:Prognosis; D012307:Risk Factors; D051759:Xeroderma Pigmentosum Group D Protein / Q000235:genetics*
chemical_list: D051759:Xeroderma Pigmentosum Group D Protein; C497292:ERCC2 protein, human
references.citation: Nat Genet. 1998 Oct;20(2):184-8
references.pmid: 9771713
references.citation: Biometrics. 1994 Dec;50(4):1088-101
references.pmid: 7786990
references.citation: J Thorac Oncol. 2010 Sep;5(9):1337-45
references.pmid: 20651612
references.citation: Lancet. 1997 Oct 18;350(9085):1182
references.pmid: 9343537
references.citation: J Natl Cancer Inst. 2000 Jun 7;92(11):874-97
references.pmid: 10841823
references.citation: Int J Colorectal Dis. 2011 Oct;26(10):1257-64
references.pmid: 21541661
references.citation: Int J Hyg Environ Health. 2004 Sep;207(4):301-13
references.pmid: 15471094
references.citation: Lancet Oncol. 2009 Aug;10(8):772-84
references.pmid: 19625214
references.citation: Breast Cancer Res Treat. 2010 Nov;124(2):531-41
references.pmid: 20379847
references.citation: BMJ. 1997 Sep 13;315(7109):629-34
references.pmid: 9310563
references.citation: World J Gastroenterol. 2011 May 14;17(18):2343-8
references.pmid: 21633601
references.citation: Carcinogenesis. 2000 May;21(5):965-71
references.pmid: 10783319
references.citation: Am J Epidemiol. 2005 Jan 1;161(1):1-14
references.pmid: 15615908
references.citation: Breast Cancer Res Treat. 2010 Nov;124(1):229-35
references.pmid: 20204500
references.citation: Carcinogenesis. 2004 May;25(5):757-63
references.pmid: 14729591
references.citation: BMJ. 2003 Sep 6;327(7414):557-60
references.pmid: 12958120
references.citation: J Dermatol Sci. 2000 May;23(1):1-11
references.pmid: 10699759
references.citation: J Natl Cancer Inst. 1959 Apr;22(4):719-48
references.pmid: 13655060
references.citation: Control Clin Trials. 1986 Sep;7(3):177-88
references.pmid: 3802833
references.citation: Mol Biol Rep. 2012 Jan;39(1):57-69
references.pmid: 21614524
references.citation: Carcinogenesis. 2005 Jan;26(1):169-75
references.pmid: 15471894
references.citation: Mutat Res. 2002 Nov 30;509(1-2):201-10
references.pmid: 12427539
references.citation: Mutagenesis. 2002 Nov;17(6):463-9
references.pmid: 12435843
references.citation: Cancer Epidemiol Biomarkers Prev. 1999 Jan;8(1):77-81
references.pmid: 9950243